tetano
Editor, Senior Moderator
Sci Rep
. 2025 Feb 13;15(1):5337.
doi: 10.1038/s41598-025-89930-0. Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice
Dylan T Boehm[SUP] 1 2 [/SUP], Kaitlyn M Landreth[SUP] 1 [/SUP], Emel Sen Kilic[SUP] 1 2 [/SUP], Katherine S Lee[SUP] 1 2 [/SUP], Bishal Misra[SUP] 3 [/SUP], Sharan Bobbala[SUP] 3 [/SUP], F Heath Damron[SUP] 1 2 [/SUP], Tracy W Liu[SUP] 4 5 [/SUP]
Affiliations
Immunotherapies are effective for cancer treatment but are limited in 'cold' tumor microenvironments due to a lack of infiltrating CD8[SUP]+[/SUP] T cells, key players in the anti-cancer immune response. The onset of the COVID-19 pandemic sparked the widespread use of mRNA-formulated vaccines and is well documented that vaccination induces a Th1-skewed immune response. Here, we evaluated the effects of an intratumoral injection of the mRNA COVID-19 vaccine in subcutaneous melanoma tumor mouse models. Tumor growth and survival studies following a single intratumoral injection of the COVID-19 vaccine showed significant tumor suppression and prolonged survival in established B16F10 subcutaneous tumor-bearing mice. mRNA vaccine treatment resulted in a significant increase in CD8[SUP]+[/SUP] T cell infiltration into the tumor microenvironment, as observed using intravital imaging and flow cytometry. Further tumor growth suppression was achieved using additional mRNA vaccine treatments. Combination administration of mRNA vaccine with immune checkpoint therapies demonstrated enhanced effects, further delaying tumor growth and improving the survival time of tumor-bearing mice. This study demonstrates that mRNA vaccines may be used as adjuvants for immunotherapies.
Keywords: COVID-19 vaccine; Immunotherapy; Melanoma; T cell infiltration; mRNA vaccine.
. 2025 Feb 13;15(1):5337.
doi: 10.1038/s41598-025-89930-0. Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice
Dylan T Boehm[SUP] 1 2 [/SUP], Kaitlyn M Landreth[SUP] 1 [/SUP], Emel Sen Kilic[SUP] 1 2 [/SUP], Katherine S Lee[SUP] 1 2 [/SUP], Bishal Misra[SUP] 3 [/SUP], Sharan Bobbala[SUP] 3 [/SUP], F Heath Damron[SUP] 1 2 [/SUP], Tracy W Liu[SUP] 4 5 [/SUP]
Affiliations
- PMID: 39948424
- DOI: 10.1038/s41598-025-89930-0
Immunotherapies are effective for cancer treatment but are limited in 'cold' tumor microenvironments due to a lack of infiltrating CD8[SUP]+[/SUP] T cells, key players in the anti-cancer immune response. The onset of the COVID-19 pandemic sparked the widespread use of mRNA-formulated vaccines and is well documented that vaccination induces a Th1-skewed immune response. Here, we evaluated the effects of an intratumoral injection of the mRNA COVID-19 vaccine in subcutaneous melanoma tumor mouse models. Tumor growth and survival studies following a single intratumoral injection of the COVID-19 vaccine showed significant tumor suppression and prolonged survival in established B16F10 subcutaneous tumor-bearing mice. mRNA vaccine treatment resulted in a significant increase in CD8[SUP]+[/SUP] T cell infiltration into the tumor microenvironment, as observed using intravital imaging and flow cytometry. Further tumor growth suppression was achieved using additional mRNA vaccine treatments. Combination administration of mRNA vaccine with immune checkpoint therapies demonstrated enhanced effects, further delaying tumor growth and improving the survival time of tumor-bearing mice. This study demonstrates that mRNA vaccines may be used as adjuvants for immunotherapies.
Keywords: COVID-19 vaccine; Immunotherapy; Melanoma; T cell infiltration; mRNA vaccine.